Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + etoposide + cisplatin + serplulimab
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
surufatinib + etoposide + cisplatin + serplulimab is an investigational four-drug combination regimen being evaluated as a first-line treatment for advanced or metastatic extrapulmonary neuroendocrine carcinoma (NEC) and extensive-stage small cell lung cancer (ES-SCLC). The regimen combines surufatinib, an oral small-molecule tyrosine kinase inhibitor targeting VEGFR-1/2/3, FGFR-1, and CSF-1R; serplulimab, a humanized anti-PD-1 monoclonal antibody; and the standard etoposide/cisplatin (EP) chemotherapy backbone. By combining antiangiogenic, immunomodulatory, and cytotoxic mechanisms, this regimen aims to overcome tumor immune escape and enhance antitumor efficacy. In a Phase I/II trial (NCT05747729), the combination demonstrated encouraging clinical activity with a high objective response rate in patients with extrapulmonary NEC.
- Other names
- surufatinib + EP + serplulimabsurufatinib + serplulimab + EPsurufatinib + serplulimab + etoposide + cisplatinsurufatinib plus serplulimab and EPsurufatinib plus serplulimab and etoposide/cisplatinsurufatinib, serplulimab, etoposide and cisplatin
02
Targets
DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)FGFR1 (Fibroblast growth factor receptor 1)CSF1R (Macrophage colony-stimulating factor receptor)PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on surufatinib + etoposide + cisplatin + serplulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + etoposide + cisplatin + serplulimab.